D05.1
Intraductal carcinoma in situ of breast
Clinical Classification Guidelines
Medical Intelligence & Overview
Intraductal carcinoma in situ (DCIS) of the breast is a non-invasive form of breast cancer. It is confined within the milk ducts and has not spread into the surrounding breast tissue. Although considered early-stage cancer, it requires medical attention to prevent progression. Recognized under ICD-10 code D05.1, DCIS is most commonly detected through screening methods, especially mammograms, before symptoms appear. This guide provides an overview of the causes, symptoms, diagnosis, and treatment options for intraductal carcinoma in situ of the breast.
Causes & Symptoms
Clinical Causes: Genetic factors that increase susceptibility to breast cancer Hormonal influences, particularly prolonged exposure to estrogen Family history of breast cancer or other genetic predispositions Previous history of benign breast disease Environmental factors, including radiation exposure Age-related changes in breast tissue
Key Symptoms: Typically no noticeable symptoms in early stages Detection often occurs through routine screening tests like mammograms Possible presence of a lump or thickening in the breast Unusual nipple discharge, including blood-tinged fluid Changes in the size, shape, or appearance of the breast Skin changes on the breast, such as redness or dimpling, in some cases
Diagnostic & Treatment
Diagnosis Path: The diagnosis of intraductal carcinoma in situ relies mainly on imaging and tissue sampling. Common diagnostic procedures include: - Mammography: Used as the primary screening tool, it can reveal microcalcifications suggestive of DCIS. - Ultrasound: Helps differentiate between cystic and solid lesions and guides biopsies. - Breast biopsy: Necessary for definitive diagnosis, typically performed via needle biopsy or surgical excision, where tissue is examined microscopically for cancer cells confined within the ducts. - Magnetic Resonance Imaging (MRI): Sometimes employed for detailed evaluation when mammogram or ultrasound findings are inconclusive.
Treatment Protocols: Managing DCIS aims to prevent progression to invasive breast cancer. Treatment options include: - Surgical removal: - Lumpectomy (breast-conserving surgery): Removal of the DCIS with a margin of healthy tissue. - Mastectomy: Complete removal of the affected breast, especially in cases with widespread DCIS. - Radiation therapy: Often recommended after lumpectomy to eliminate residual cancer cells. - Hormonal therapy: Such as tamoxifen, may be suggested for hormone receptor-positive DCIS to reduce recurrence risk. - Active surveillance: In selected cases, especially when the risk of progression is low, close monitoring might be considered. - Reconstruction and supportive care: After surgery, options are available to restore the breast's appearance and manage any physical or emotional impacts.
Clinical Advice & FAQs
Billing Guidance
Is D05.1 a billable ICD-10 code?
Yes, D05.1 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report D05.1?
Clinical documentation must specify the nature of Intraductal carcinoma in situ of breast and any associated comorbidities for accurate reporting.
Cite this Clinical Reference